Le Lézard19h
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EPIX
Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") of a class action securities ...
Doctors reveal the VERY surprising triggers that may be behind prostate cancer as epidemic surges 25% in four years to become the most common in Britain
The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...
Renal & Urology News15h
Missing PSA Doubling Time Detrimental in Biochemically Recurrent Prostate Cancer
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
UroToday14h
ASCO GU 2025: Outcomes for 177Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with mCRPC
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...